{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Co-Infection&page=5",
    "query": {
      "condition": "Co-Infection",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 190,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Co-Infection&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Co-Infection&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T19:14:19.047Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00983853",
      "title": "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "telaprevir or matching placebo",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ribavirin (fixed dose)",
          "type": "DRUG"
        },
        {
          "name": "ribavirin (weight-based dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 62,
      "start_date": "2009-10",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-10-10",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 11,
      "location_summary": "Beverly Hills, California • San Diego, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983853"
    },
    {
      "nct_id": "NCT02184572",
      "title": "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Measles; Mumps; Rubella",
        "Measles-Mumps-Rubella Vaccine"
      ],
      "interventions": [
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1742,
      "start_date": "2014-08-25",
      "completion_date": "2015-12-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184572"
    },
    {
      "nct_id": "NCT01185028",
      "title": "A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Nitazoxanide With Pegylated Interferon And Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 8,
      "start_date": "2010-08",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01185028"
    },
    {
      "nct_id": "NCT06060457",
      "title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone HD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1900,
      "start_date": "2023-09-25",
      "completion_date": "2024-06-07",
      "has_results": true,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 34,
      "location_summary": "Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06060457"
    },
    {
      "nct_id": "NCT05256316",
      "title": "Risks of Bacterial and Fungal Superinfection in Patients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Previously admitted COVID-19 patients in intensive care units",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Queensland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 790,
      "start_date": "2022-02-14",
      "completion_date": "2022-12-04",
      "has_results": false,
      "last_update_posted_date": "2023-05-22",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256316"
    },
    {
      "nct_id": "NCT00644761",
      "title": "PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Adefovir Dipivoxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2004-02",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-04-10",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00644761"
    },
    {
      "nct_id": "NCT00782301",
      "title": "Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B",
        "Human Immunodeficiency Virus",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-03",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2012-01-19",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 15,
      "location_summary": "Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Safety Harbor",
          "state": "Florida"
        },
        {
          "city": "Wilton Manors",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782301"
    },
    {
      "nct_id": "NCT01866930",
      "title": "Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon Lambda-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Daclatasvir (DCV)",
          "type": "DRUG"
        },
        {
          "name": "Ribasphere (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2013-07-11",
      "completion_date": "2015-08-27",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 13,
      "location_summary": "Rialto, California • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01866930"
    },
    {
      "nct_id": "NCT03318315",
      "title": "Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Avian Influenza",
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "Inactivated influenza H7N9 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Quadrivalent Inactivated Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate Buffered Saline (PBS) diluent",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 149,
      "start_date": "2018-02-20",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03318315"
    },
    {
      "nct_id": "NCT02220868",
      "title": "Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir, Ribavirin, and Stribild",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Michael's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2014-07",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-10-29T19:14:19.047Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02220868"
    }
  ]
}